Provided by Tiger Trade Technology Pte. Ltd.

Metagenomi Technologies, LLC

1.39
+0.02001.46%
Post-market: 1.390.00000.00%17:26 EDT
Volume:221.58K
Turnover:312.37K
Market Cap:52.19M
PE:-0.59
High:1.45
Open:1.40
Low:1.38
Close:1.37
52wk High:3.95
52wk Low:1.23
Shares:37.55M
Float Shares:25.28M
Volume Ratio:1.07
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3600
EPS(LYR):-2.3634
ROE:-44.67%
ROA:-21.99%
PB:0.33
PE(LYR):-0.59

Loading ...

Metagenomi Inc - Ind/Cta Submissions for Mgx-001 Expected by End of 2026; First-in-Human Study in 2027

THOMSON REUTERS
·
Jan 12

Unveiling 3 Undervalued Asian Small Caps With Insider Buying

Simply Wall St.
·
Dec 23, 2025

Middle East Capital Fuels US Data Center Boom

Deep News
·
Dec 11, 2025

MGX Resources Says FIRB Approves Acquisition of 50% Stake in Northern Territory Gold Project Joint Venture

MT Newswires Live
·
Dec 03, 2025

MGX Resources Changes Name from Mount Gibson Iron

MT Newswires Live
·
Dec 03, 2025

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

GlobeNewswire
·
Dec 01, 2025

Metagenomi Inc : Jefferies Cuts Target Price to $9 From $21

THOMSON REUTERS
·
Nov 18, 2025

Metagenomi Inc. to Present at Jefferies Global Healthcare Conference in London

Reuters
·
Nov 17, 2025

Chardan Cuts Price Target on Metagenomi to $7 From $11, Keeps Buy Rating

MT Newswires Live
·
Nov 13, 2025

Metagenomi price target lowered to $7 from $11 at Chardan

TIPRANKS
·
Nov 13, 2025

Metagenomi Announces Positive Preclinical Data for MGX-001

TIPRANKS
·
Nov 12, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 12, 2025

Mount Gibson Iron Limited Announces AGM Results and Name Change Approval

TIPRANKS
·
Nov 12, 2025

BRIEF-Metagenomi Inc - MGX-001 Demonstrated Curative FVIII Activity In Non-Human Primates

Reuters
·
Nov 12, 2025

Metagenomi Inc -Mgx-001 Demonstrated Curative Fviii Activity in Non-Human Primates

THOMSON REUTERS
·
Nov 12, 2025

Metagenomi: Pre-Ind Regulatory Meeting Expected in Q4 2025 With Ind & Clinical Trial Application Submissions Expected in 4Q 2026

THOMSON REUTERS
·
Nov 12, 2025

Metagenomi CEO Brian Thomas to transition out of role, Jian Irish to succeed

TIPRANKS
·
Nov 12, 2025

Metagenomi reports Q3 EPS (55c), consensus (53c)

TIPRANKS
·
Nov 12, 2025

Metagenomi reports new dose range finding data from MGX-001 hemophilia A program

TIPRANKS
·
Nov 12, 2025

Metagenomi reduces workforce by 25%

TIPRANKS
·
Nov 12, 2025